_id
6915fda1bc934aba376b2812
Ticker
SPPH
Name
Spencer Pharmaceutical Inc
Exchange
OTCCE
Address
8 Faneuil Hall Marketplace, Boston, MA, United States, 02109
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
-
Description
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Last Close
0.0001
Volume
-
Current Price
0.0001
Change
0
Last Updated
2025-11-24T11:53:52.271Z
Image
-
Ipo Date
-
Market Cap
1342960
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2010-12-31
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
754536
Operating Income
-754536
Interest Expense
0
Pretax Income
-754536
Net Income
-754536
Eps
-
Dividends Per Share
0
Shares Outstanding
0
Income Tax Expense
0
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
0
Cash
455928
Short Term Investments
0
Receivables
0
Inventories
0
Total Current Assets
455928
Property Plant Equipment
0
Total Assets
772197
Payables
471030
Short Term Debt
0
Long Term Debt
0
Total Liabilities
1643223
Equity
-871026
Depreciation
0
Change In Working Capital
-
Cash From Operations
536665
Capital Expenditures
0
Cash From Investing
-147436
Cash From Financing
68341
Net Change In Cash
455629
PE
-
PB
0
ROE
86.6261167864105
ROA
-97.71288932746437
FCF
536665
Fcf Percent
-
Piotroski FScore
2
Health Score
46
Deep Value Investing Score
3.5
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
7.3
Garp Investing Score
3.5
Growth Investing Score
3.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
4.5
Value Investing Score
3
Quarters > 0 > quarter
2010-12-31
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
754536
Quarters > 0 > income Statement > operating Income
-754536
Quarters > 0 > income Statement > interest Expense
0
Quarters > 0 > income Statement > pretax Income
-754536
Quarters > 0 > income Statement > net Income
-754536
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
0
Quarters > 0 > income Statement > shares Outstanding
0
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
455928
Quarters > 0 > balance Sheet > short Term Investments
0
Quarters > 0 > balance Sheet > receivables
0
Quarters > 0 > balance Sheet > inventories
0
Quarters > 0 > balance Sheet > total Current Assets
455928
Quarters > 0 > balance Sheet > property Plant Equipment
0
Quarters > 0 > balance Sheet > total Assets
772197
Quarters > 0 > balance Sheet > payables
471030
Quarters > 0 > balance Sheet > short Term Debt
0
Quarters > 0 > balance Sheet > long Term Debt
0
Quarters > 0 > balance Sheet > total Liabilities
1643223
Quarters > 0 > balance Sheet > equity
-871026
Quarters > 0 > cash Flow > net Income
-754536
Quarters > 0 > cash Flow > depreciation
0
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
536665
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-147436
Quarters > 0 > cash Flow > cash From Financing
68341
Quarters > 0 > cash Flow > net Change In Cash
455629
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
0
Quarters > 0 > ratios > ROE
86.6261167864105
Quarters > 0 > ratios > ROA
-97.71288932746437
Quarters > 0 > ratios > FCF
536665
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
46
Quarters > 1 > quarter
2010-09-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
0
Quarters > 1 > income Statement > gross Profit
0
Quarters > 1 > income Statement > operating Expenses
75768
Quarters > 1 > income Statement > operating Income
-75768
Quarters > 1 > income Statement > interest Expense
0
Quarters > 1 > income Statement > pretax Income
-75768
Quarters > 1 > income Statement > net Income
-75768
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
0
Quarters > 1 > income Statement > shares Outstanding
0
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
299
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
0
Quarters > 1 > balance Sheet > inventories
0
Quarters > 1 > balance Sheet > total Current Assets
299
Quarters > 1 > balance Sheet > property Plant Equipment
0
Quarters > 1 > balance Sheet > total Assets
111532
Quarters > 1 > balance Sheet > payables
155146
Quarters > 1 > balance Sheet > short Term Debt
0
Quarters > 1 > balance Sheet > long Term Debt
0
Quarters > 1 > balance Sheet > total Liabilities
303855
Quarters > 1 > balance Sheet > equity
-192323
Quarters > 1 > cash Flow > net Income
-75768
Quarters > 1 > cash Flow > depreciation
0
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-1629
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
52295
Quarters > 1 > cash Flow > cash From Financing
-55500
Quarters > 1 > cash Flow > net Change In Cash
299
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
0
Quarters > 1 > ratios > ROE
39.396224060564776
Quarters > 1 > ratios > ROA
-67.93386651364631
Quarters > 1 > ratios > FCF
-1629
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
45
Quarters > 2 > quarter
2010-06-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
0
Quarters > 2 > income Statement > gross Profit
0
Quarters > 2 > income Statement > operating Expenses
56446
Quarters > 2 > income Statement > operating Income
-56446
Quarters > 2 > income Statement > interest Expense
0
Quarters > 2 > income Statement > pretax Income
-56446
Quarters > 2 > income Statement > net Income
-56446
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
0
Quarters > 2 > income Statement > shares Outstanding
0
Quarters > 2 > income Statement > income Tax Expense
0
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
0
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
0
Quarters > 2 > balance Sheet > inventories
0
Quarters > 2 > balance Sheet > total Current Assets
0
Quarters > 2 > balance Sheet > property Plant Equipment
0
Quarters > 2 > balance Sheet > total Assets
108028
Quarters > 2 > balance Sheet > payables
75243
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
0
Quarters > 2 > balance Sheet > total Liabilities
217293
Quarters > 2 > balance Sheet > equity
-109265
Quarters > 2 > cash Flow > net Income
-56446
Quarters > 2 > cash Flow > depreciation
0
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
53696
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-81764
Quarters > 2 > cash Flow > cash From Financing
27750
Quarters > 2 > cash Flow > net Change In Cash
299
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
0
Quarters > 2 > ratios > ROE
51.659726353361094
Quarters > 2 > ratios > ROA
-52.251268189728584
Quarters > 2 > ratios > FCF
53696
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
46
Quarters > 3 > quarter
2010-03-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
0
Quarters > 3 > income Statement > gross Profit
0
Quarters > 3 > income Statement > operating Expenses
56446
Quarters > 3 > income Statement > operating Income
-56446
Quarters > 3 > income Statement > interest Expense
0
Quarters > 3 > income Statement > pretax Income
-56446
Quarters > 3 > income Statement > net Income
-56446
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
0
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
0
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
0
Quarters > 3 > balance Sheet > inventories
0
Quarters > 3 > balance Sheet > total Current Assets
0
Quarters > 3 > balance Sheet > property Plant Equipment
0
Quarters > 3 > balance Sheet > total Assets
108028
Quarters > 3 > balance Sheet > payables
75243
Quarters > 3 > balance Sheet > short Term Debt
0
Quarters > 3 > balance Sheet > long Term Debt
0
Quarters > 3 > balance Sheet > total Liabilities
217293
Quarters > 3 > balance Sheet > equity
-109265
Quarters > 3 > cash Flow > net Income
-56446
Quarters > 3 > cash Flow > depreciation
0
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
53696
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-81764
Quarters > 3 > cash Flow > cash From Financing
27750
Quarters > 3 > cash Flow > net Change In Cash
299
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
0
Quarters > 3 > ratios > ROE
51.659726353361094
Quarters > 3 > ratios > ROA
-52.251268189728584
Quarters > 3 > ratios > FCF
53696
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
46
Valuation > metrics > PB
0
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
86.6261167864105
Profitability > metrics > ROA
-165.4945517713323
Profitability > final Score
55
Profitability > verdict
Weak
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.9679383478759315
Liquidity > metrics > Quick Ratio
0.9679383478759315
Liquidity > final Score
58
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
70
Prev Profitabilities > 2
70
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
10
Prev Liquidities > 1
10
Prev Liquidities > 2
10
Updated At
2026-01-20T22:37:01.501Z
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AJasa Kita proposes land acquisition from newly appointed chairman's spouse - The Edge Malaysia
12/23/2025
Jasa Kita proposes land acquisition from newly appointed chairman's spouse The Edge Malaysia
Read more →(Last Updated 2010-12-31)
Health Score
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Spencer Pharmaceutical Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2010-12-31)
(Last Updated 2010-12-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2010-12-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2010-12-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.